A5073301255- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Prenatal Screening and Diagnostics
- Estrogen and related hormone effects
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- Cancer Research and Treatments
- Science, Research, and Medicine
- BRCA gene mutations in cancer
- Renal Transplantation Outcomes and Treatments
- DNA Repair Mechanisms
- Virus-based gene therapy research
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Global Cancer Incidence and Screening
- Genomic variations and chromosomal abnormalities
- Cancer Cells and Metastasis
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
University of Illinois Chicago
2020-2025
University of Illinois Urbana-Champaign
2021-2024
University of Washington
2014-2023
Fred Hutch Cancer Center
2013-2023
University of Washington Medical Center
2011-2022
University of Chicago Medical Center
2021-2022
Seattle Cancer Care Alliance
2009-2020
Northwest Medical Specialties
2017
Cancer Research Center
2009-2017
Neurological Surgery
2016
Abstract Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe development a robust precision cancer care platform integrates whole-exome sequencing with living biobank enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures 19 xenograft (PDX) models have been established from 769 patients enrolled in...
The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients stage I human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).Patients centrally confirmed HER2+ BC were randomly assigned 3:1 T-DM1 or TH received 3.6 mg/kg IV every 3 weeks for 17 cycles T 80 mg/m2 H once week × 12 (4 load →2 mg/kg), followed by...
Cisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, has antineoplastic activity in triple-negative breast cancer (TNBC) BRCA mutation-associated cancer. This phase I study assessed veliparib cisplatin vinorelbine.A 3+3 dose-escalation design evaluated administered twice daily for 14 days (75 mg/m(2) day 1) (25 1, 8) every 21 days, 6 to 10 cycles, followed by monotherapy. Pharmacokinetics, measurement of poly(ADP-ribose) peripheral blood mononuclear cells, preliminary...
Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need.
Abstract Fetal microchimerism (FMc) describes long-term persistence of small numbers fetal-derived allogeneic cells in the mother. Although FMc has been implicated as a mechanism autoimmune disease, it may confer beneficial effect with immune surveillance malignant cells. We hypothesized that imparts protective against breast cancer. Two observations provided rationale for study hypothesis. First, convey risk reduction recurrent malignancy hematopoietic cell transplantation. Second, reduced...
Changes in tumor metabolism from positron emission tomography (PET) locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NC) are predictive of pathologic response. Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters the standardized uptake value (SUV) as predictors response, disease-free survival (DFS), and overall (OS).Seventy-five LABC underwent FDG prior at midpoint NC. delivery (K(1)), flux (K(i)), SUV...
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial <sup>18</sup>F-FDG PET was predictive time to skeletal-related events (tSRE) and progression (TTP). <sup>18</sup>F-NaF improves metastasis detection compared with scanning. We prospectively tested predict tSRE, TTP, overall survival (OS) in patients bone-dominant metastatic (MBC). <b>Methods:</b> Patients MBC were imaged before starting new (scan1) again at a range times centered...
There is no reliable serum marker available to monitor incipient pancreas or islet-cell rejection. We tested the hypothesis that quantification of donor-specific genomic DNA in (from tissue damage) can serve as a rejection.Using recently developed panel HLA-specific quantitative PCR assays (Q-PCR), we 158 sera from 42 pancreas-kidney transplant recipients. Temporally related biopsies for 65 permitted analysis correlation donor concentrations with rejection.Donor were higher recipients who...
BackgroundPrior pregnancy is known to protect against development of breast cancer. Recent studies have demonstrated that has the capacity establish small numbers immunologically active fetal-derived cells in mother, a phenomenon as fetal microchimerism (FMc). We asked whether presence FMc, routinely acquired during pregnancy, protective factor for cancer.Methodology/Principal FindingsDNA extracts from peripheral blood specimens were obtained population-based case-control study risk factors...
Background Hormone receptor‐positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. Purpose To evaluate prognostic potential of diffusion‐weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10‐year recurrence risk. Study Type Retrospective. Subjects In all, 107 consecutive (from 2/2010 1/2013) estrogen receptor...
Background: Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits less significant is unknown. Objective: To compare outcomes breast cancer trials had they been using contemporary treatments with used treatments. Design: Computer simulation model 3 virtual similar reductions advanced-stage cases but reflecting treatment patterns 1975 (prechemotherapy...
BackgroundHomologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) becoming a preferred treatment option. However, considerable proportion these carcinomas acquire resistance or harbour de novo resistance, posing significant challenge to treatment.MethodsTo identify new combinatorial therapeutics overcome PARPi, we employed high-throughput conditional RNAi and drug screening patient-derived cancer cells. To...
Background: Parental cancer represents a substantial psychological threat to children, but little is known about the relative impact of advanced compared early-stage on children's behavioral–emotional functioning.
Abstract Background: Lung cancer is the leading cause of cancer-related mortality globally. While screening and predictive analytics provide insights into its pathogenesis, role social determinants health (SDOH), particularly in urban U.S. populations, unexplored at individual level. This study examines associations between SDOH factors lung within Chicago. Methods: An IRB-approved protocol was used to build a retrospective cohort 11, 154 patients (60% African American [AA], 30% White, 10%...
Abstract Background: The Precision Oncology Tumor Board (POTB) at the University of Illinois Chicago (UIC) advances cancer treatment through molecular profiling and personalized recommendations. Studies link tumor boards to improved outcomes. POTB integrates multidisciplinary expertise across institutions provide therapeutic trial recommendations based on clinical genomic data. PROMOTE (PRecision Oncology: Measuring Outcomes Treatment Effectiveness) study is a retrospective analysis cases...
HLA class II genes provide the strongest genetic contribution to rheumatoid arthritis (RA). HLA-DRB1 alleles encoding sequence DERAA are RA-protective. Paradoxically, RA risk is increased in women with DERAA+ children born prior onset. We developed a sensitive qPCR assay specific for DERAA, and found 53% of DERAA-/- had microchimerism (Mc; pregnancy-derived allogeneic cells) carrying (DERAA-Mc) vs. 6% healthy women. DERAA-Mc quantities correlated an RA-risk background including DERAA-binding...